Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Corinne Bousquet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2501-0593; OpenAlex author ID A5078518284. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
123
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 23

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression. Co-author DOI 10.1038/s43018-026-01265-5↗
  3. ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Co-author DOI 10.1038/s41416-024-02904-3↗
  4. Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer mod… Co-author DOI 10.1038/s41419-025-07747-1↗
  5. The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41417-024-00814-3↗
  6. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-326610↗
  7. Pancreatic cancer orthotopic graft in a murine model. Co-author DOI 10.1590/acb382823↗
  8. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Last author DOI 10.1002/path.6011↗
  9. Translational alterations in pancreatic cancer: a central role for the integrated stress response. Co-author DOI 10.1093/narcan/zcac031↗
  10. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Co-author DOI 10.3390/cancers14174265↗
  11. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Co-author DOI 10.3390/cancers14246160↗
  12. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Last author DOI 10.1016/j.jcmgh.2021.01.008↗
  13. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer Co-author DOI 10.1016/j.pan.2021.05.117↗
  14. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  15. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Co-author DOI 10.15252/emmm.202012010↗
  16. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  17. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317570↗
  18. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. Co-author DOI 10.1172/jci.insight.121951↗
  19. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Co-author DOI 10.1016/j.canlet.2018.06.023↗
  20. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2016.10.010↗
  21. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  22. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Last author DOI 10.18632/oncotarget.9296↗
  23. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Co-author DOI 10.1038/cddis.2014.557↗

Closest collaborators

The 25 strongest of 123 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christine Jean · 9 shared papers, 2016–2026 · strength 1.09
  2. Stéphane Pyronnet · 8 shared papers, 2016–2026 · strength 0.90
  3. Cindy Neuzillet · 7 shared papers, 2019–2026 · strength 0.88
  4. Yvan Martineau · 7 shared papers, 2016–2026 · strength 0.81
  5. Rémy Nicolle · 6 shared papers, 2021–2026 · strength 0.76
  6. Nelson Dusetti · 6 shared papers, 2015–2026 · strength 0.63
  7. Rémi Samain · 7 shared papers, 2016–2022 · strength 0.61
  8. Sauyeun Shin · 4 shared papers, 2019–2026 · strength 0.58
  9. Jerome F. Cros · 5 shared papers, 2019–2026 · strength 0.56
  10. Richard Tomasini · 6 shared papers, 2015–2023 · strength 0.48
  11. Christel Larbouret · 3 shared papers, 2018–2025 · strength 0.44
  12. Pierre‐Emmanuel Colombo · 3 shared papers, 2018–2025 · strength 0.44
  13. Juan Iovanna · 4 shared papers, 2015–2026 · strength 0.40
  14. Jérémy Nigri · 5 shared papers, 2015–2023 · strength 0.39
  15. Annemilaï Tijeras‐Raballand · 3 shared papers, 2019–2023 · strength 0.39
  16. Kévin Bigot · 2 shared papers, 2025 · strength 0.38
  17. Marine Bruciamacchie · 2 shared papers, 2025 · strength 0.38
  18. Matteo Ponzo · 3 shared papers, 2021–2022 · strength 0.32
  19. Ilaria Cascone · 3 shared papers, 2021–2022 · strength 0.32
  20. Jérôme Raffenne · 3 shared papers, 2021–2022 · strength 0.32
  21. Charline Ogier · 2 shared papers, 2018–2026 · strength 0.25
  22. Anaïs Debesset · 2 shared papers, 2022 · strength 0.23
  23. Mounira Chalabi‐Dchar · 2 shared papers, 2022 · strength 0.23
  24. José Laurent Cohen · 2 shared papers, 2022 · strength 0.23
  25. Christophe Tournigand · 2 shared papers, 2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.